Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína2. fázis

Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Tianjin (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
122 fő, tervezett
Kezdés
2026. márc.
Várható befejezés
2028. márc.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Rituximab
  • Daratumumab
A regiszteradat frissítve
2026. január 23.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children and teenagers with primary immune thrombocytopenia (ITP, a low platelet count caused by the immune system) whose steroid treatment did not work or stopped working. It compares Daratumumab with Rituximab.

Életkor
6 to under 18 years
Nem
Male or female
A betegség stádiuma
Primary ITP diagnosed at least three months ago. Platelet count below 30×10^9/L within 24 hours before the first dose, and no count above 35×10^9/L at screening. ECOG performance status of 2 or less (able to care for yourself).
Korábbi kezelés
Steroid (glucocorticoid) treatment must have failed, stopped working, or the disease came back. Must have responded before (platelets at least 50×10^9/L) to first-line steroids and/or intravenous immunoglobulin. One stable maintenance medicine is allowed, such as glucocorticoids (up to 0.5 mg/kg prednisone or equivalent) or TPO receptor agonists, stable for at least 4 weeks. Cannot have had a CD20 or CD38 antibody before.
Biomarker vagy leletérték
Platelet count below 30×10^9/L. Must test negative for HIV, syphilis, active hepatitis B and hepatitis C.

A részvétel fő kizáró okai

  • Prior CD20 or CD38 antibody treatment
  • Autoimmune hemolytic anemia or thrombocytopenia from another cause
  • Blood clots, or severe bleeding such as bleeding in the brain, within the past 12 months
  • Stem cell or organ transplant, or cancer within the past 5 years
  • Serious or recent infections, or a weak immune system

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥6,<18 years, male or female
  • Before enrollment, the subjects have been clinically diagnosed with primary immune thrombocytopenia for no less than three months according to the American Society of Hematology guidelines 2011 Evidence-Based Practice Guideline (Neunert et al. 2011) or the International Consensus Report for the Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as applicable locally
  • Patients have failed glucocorticoid therapy (either due to inefficacy, efficacy could not be maintained, or relapse). Patients were required to have a response history (PLT≥50×10\^9/L) to standard first-line treatment of ITP (glucocorticoid and/or intravenous immunoglobulin)
  • Subjects with a platelet count of <30×10\^9/L within the 24 hours prior to the first dose of the study drug; The mean platelet count of at least two separate assessments (at least 1 week apart) <30×10\^9/L during the screening visit, and no platelet count > 35×10\^9/L
  • ECOG performance status score of ≤2
  • Enrollment of subjects receiving maintenance therapy with a stable dosage is permitted, including glucocorticoids (≤0.5 mg/kg of prednisone or equivalent) or TPO receptor agonists. However, at the time of enrollment, subjects are restricted to using only one concomitant medication with a stable dose, and the concomitant medication must have been stable for a minimum of 4 weeks prior to the initial infusion of the study drug
  • Subjects and the legal guardian comprehensively understand and can adhere to the study protocol requirements and willingly signed the informed consent form

Ki nem vehet részt

  • Subjects who have participated in any other investigational drug studies (including vaccine studies) or been exposed to other investigational drugs within the first 4 weeks or 5 half-lives (whichever was longer) prior to the first dose of study drug
  • Subjects who have used anticoagulants or any agents with antiplatelet effects, such as aspirin, within 3 weeks prior to the first dose of study drug
  • Subjects who have been treated with medications including azathioprine, danazol, dapsone, cyclosporine A, tacrolimus, and sirolimus within 4 weeks prior to the first dose of study drug. Subjects who have receive medications including cyclophosphamide and vindesine within 6 months prior to the first dose of study drug
  • Subjects who have undergone splenectomy within 6 months prior to the first dose of study drug
  • Subjects who have received live vaccines within 4 weeks prior to the first dose of study drug, or plan to receive any live vaccines during the course of the study
  • Subjects who have undergone allogeneic stem cell transplantation or organ transplantation
  • Subjects with a clinically significant medical history, as perceived by investigators, that will pose risks to subjects' safety during the study or potentially affect the safety or efficacy analyses, includes major clinical histories such as circulatory system abnormalities, endocrine system abnormalities, nervous system diseases, blood system diseases, immune system diseases, mental diseases and metabolic abnormalities and so on. e.g., subjects with acute myocardial infarction, unstable angina pectoris, or severe arrhythmias (multifocal ventricular premature contractions, ventricular tachycardia, or ventricular fibrillation) within the 6 months before screening ; New York Heart Association (NYHA) class III-IV heart failure; subjects who were known to have had moderate or severe persistent asthma or chronic obstructive pulmonary disease within the 5 years prior to screening, or whose condition was currently poorly controlled
  • Subjects with a history of severe recurrent or chronic infections, or acute infections requiring systemic treatment with antibiotics, antiviral drugs, antiparasitic drugs, anti-amoebic drugs, or antifungal drugs within 4 weeks prior to the first dose and during the screening period, or superficial skin infections requiring systemic treatment within one week prior to the first dose of study drug. Notably, after the resolution of the infection, the subject may be re-screened
  • Subjects with a history of using CD20 monoclonal antibody or CD38 monoclonal antibody
  • Subjects who are diagnosed with autoimmune hemolytic anemia or various secondary thrombocytopenic disorders
  • Subjects with history of any thrombotic or embolic events or extensive and severe bleeding, such as hemoptysis, major upper gastrointestinal bleeding, intracranial hemorrhage, or the presence of sepsis or other irregular bleeding within the 12 months preceding the initiation of the first dose of study drug
  • Subjects who are diagnosed with Myelodysplastic syndromes (MDS); Subjects with a with a history of malignancy within the 5 years prior to screening (excluding completely cured in situ cervical cancer and non-metastatic skin squamous cell carcinoma or basal cell carcinoma)
  • Subjects with a history of known or suspected immunosuppression, including invasive opportunistic infections such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis pneumonia, and aspergillosis, even if the infection has resolved; or unusually frequent, recurrent, or prolonged infections (as judged by the investigator)
  • Positive for HIV antibodies or syphilis antibodies
  • Subjects test positive for Hepatitis B surface antigen (HBsAg) or subjects test positive for hepatitis B core antibody and HBV-DNA (through polymerase chain reaction testing), or subjects test positive for hepatitis C virus antibody and HCV-RNA during the screening period. Subjects with positive hepatitis B core antibody but negative HBV-DNA can be enrolled, with HBV-DNA monitoring every 4 weeks
  • Any other conditions unsuitable for participation in this study, as assessed by the investigator
  • Subjects who have received emergency treatment for ITP (e.g., methylprednisolone, platelet transfusion, intravenous immunoglobulin infusion, or thrombopoietin receptor agonist therapy) within 2 weeks prior to the first dose of study drug
  • Significant laboratory abnormalities during screening included:; Alanine aminotransferase or aspartate aminotransferase greater than three times the upper limit of normal (ULN); Total bilirubin greater than 1.5 times the ULN (note: subjects diagnosed with Gilbert syndrome based on medical records should not be excluded based on this criterion); absolute neutrophil count < 1500/mm3; hemoglobin < 9g/dL; IgG < 500 mg/dL; lymphocyte count < 500/mm3; Creatinine clearance (CrCl) < 30 mL/min (i.e., CrCl ≥30 mL/min is allowed)

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 6 és 18 év között vagy?

Helyszínek itt: Kína

  • Chinese Academy of Medical Science and Blood Disease HospitalTianjin, KínaContact: Lei Zhang, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with Rituximab in pediatric ITP patients.This study will be conducted in pediatric ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.

A vizsgálat 2 csoportja

  • RituximabMár használt kezelés, összehasonlításként

    Rituximab (375mg/m2) was given once.

  • Daratumumab(Anti-CD38 Monoclonal Antibody )A vizsgált kezelés

    Daratumumab(anti-CD38 monoclonal antibody )(16mg/kg) was given once a week for eight times

    Kezelés: Daratumumab

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Open-label Study To Compare The Efficacy And Safety Of Daratumumab Versus Rituximab in ITP Patients Who Failed or Relapsed After Glucocorticoid Therapy
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07362238: ki vehet részt
A regiszteradat frissítve
2026. január 23.